97 related articles for article (PubMed ID: 831730)
1. Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Johnson RK
Biochem Pharmacol; 1977 Jan; 26(1):81-4. PubMed ID: 831730
[No Abstract] [Full Text] [Related]
2. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
3. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
Swyryd EA; Seaver SS; Stark GR
J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
[No Abstract] [Full Text] [Related]
4. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
5. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
7. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
Harrison SD; Giles HD; Denine EP
Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
[No Abstract] [Full Text] [Related]
8. Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
Tsuboi KK; Edmunds NH; Kwong LK
Cancer Res; 1977 Sep; 37(9):3080-7. PubMed ID: 884665
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
[No Abstract] [Full Text] [Related]
10. m-AMSA and PALA: two new agents in cancer chemotherapy.
Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Kensler TW; Reck LJ; Cooney DA
Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
[No Abstract] [Full Text] [Related]
12. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Karle JM; Anderson LW; Dietrick DD; Cysyk RL
Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
[No Abstract] [Full Text] [Related]
14. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
15. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Karle JM; Anderson LW; Erlichman C; Cysyk RL
Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
[TBL] [Abstract][Full Text] [Related]
17. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
18. Phosphonacetyl-L-aspartate: an aspartate transcarbamylase inhibitor causing larval death and rudimentary wing phenocopies in Drosophila melanogaster.
Holaday BJ; Fristrom JW
Experientia; 1977 Apr; 33(4):428-30. PubMed ID: 405235
[No Abstract] [Full Text] [Related]
19. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
20. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
